Genmab


Healthy Q1 prompts guidance upgrade

13/05/22 -"Genmab reported a healthy set of Q1 results. This impressive performance was witnessed across the offerings, which were again led by Darzalex. Despite maintaining aggressive spending plans, the 2022 ..."

Pages
51
Language
English
Published on
13/05/22
You may also be interested by these reports :
25/05/22
Considering the group was already facing multiple headwinds – deteriorating generics pricing environment in the US, market share losses for its ...

18/05/22
We have updated our model to incorporate the impact of the spin-off of the API (active pharmaceutical ingredient) business, which had listed ...

18/05/22
Given the sustained recovery in the plasma supply – now back to pre-pandemic levels – Grifols has been benefiting from a recovery in investor ...

17/05/22
As Sensei has prioritised development of SNS-101 over the SNS-401-NG programme – possibly to manage cash burn, considering the recent decline in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO